Alumis reported positive top-line results from two Phase 3 trials of envudeucitinib (envu), a selective oral TYK2 inhibitor, meeting co-primary and multiple secondary endpoints in patients with moderate-to-severe plaque psoriasis. The company said responses deepened over time and that it plans regulatory filings later this year; executives described 2026 as a value-inflection year driven by the data. Financial market reaction was immediate—shares more than doubled on the news. Company releases provided efficacy metrics and safety summaries; Alumis highlighted envu’s profile relative to competing oral TYK2s and positioned a submission to regulators in the second half of 2026. Investors and competitors will watch regulatory interactions and any differentiation on safety or convenience that could shape market access against established biologics and emerging oral options.